David Wheadon appointed to board of directors at Seaport Therapeutics

Natalia Elliot | August 14, 2024 | News story | |  Corporate, Seaport Therapeutics, appointment 

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Daphne Zohar, founder and chief executive officer at Seaport said:“It is our pleasure to welcome David Wheadon to our board of directors,”

Dr Wheadon is a pharmaceutical leader who most recently served as senior vice president, Global Regulatory Affairs, Patient Safety and Quality Assurance at AstraZeneca. He has more than three decades of experience in clinical strategy, regulatory affairs and global health policies.

Advertisement

While at AstraZeneca, he oversaw the global regulatory affairs, patient safety and quality assurance organisation. He also drove regulatory strategy for the development and approval of the company’s product portfolio.

 Dr Wheadon is a physician and psychiatrist with more than three decades of experience in regulatory affairs. In addition to this, he also served as a member of AstraZeneca’s Global Medicines Development Leadership team and Late-Stage Product Committee, which was responsible for the progression of AstraZeneca’s late-stage portfolio through clinical development, regulatory approvals and market access.

 “Seaport has a promising pipeline of novel antidepressants and anxiolytics, and I look forward to being a part of the journey of delivering these important new treatments to the millions of patients suffering from devastating and debilitating mental health conditions, including depression and anxiety”, commented Dr Wheadon.

Natalia Elliot

Related Content

mental-health-3332122_960_720

Seaport Therapeutics doses first patient in trial of GlyphAllo for depression

Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo …

sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

white_and_ford

Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …

The Gateway to Local Adoption Series

Latest content